Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell Carcinoma
Public ClinicalTrials.gov record NCT00073125. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Randomized Study Evaluating the Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell Carcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to assess the safety and efficacy of ABT-510 in subjects with advanced renal cell carcinoma.
Study identification
- NCT ID
- NCT00073125
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 103 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2003 (Type not available)
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Aug 15, 2007
Started 2003
United States locations
- U.S. sites
- 17
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Virginia G. Piper Cancer Center | Scottsdale | Arizona | 85258 | — |
| Arizona Cancer Center | Tucson | Arizona | 85724 | — |
| UCLA School of Medicine | Los Angeles | California | 90024 | — |
| Clinical Trials and Research Associates | Montebello | California | 90640 | — |
| The Center for Hematology-Oncology | Boca Raton | Florida | 33486 | — |
| University of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| Central indiana Cancer Center | Indianapolis | Indiana | 46227 | — |
| Kansas City Cancer Centers Southwest | Overland Park | Kansas | 66210 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Kansas City Oncology and Hematology Group | Kansas City | Missouri | 64111 | — |
| Albany Regional Cancer Center | Albany | New York | 12208 | — |
| Raleigh Hematology Oncology Clinic | Cary | North Carolina | 27511 | — |
| US Oncology, P.A. | Dallas | Texas | 75246 | — |
| Texas Cancer Center | Fort Worth | Texas | 66210 | — |
| Texas Cancer Center | Fort Worth | Texas | 76104 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Baylor College of Medicine | Houston | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00073125, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 15, 2007 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00073125 live on ClinicalTrials.gov.